Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipifarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 15/20 | 0.80 |
| ▸ | FNTB known ✓ | P49356 | 15/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipifarnib SCHEMBL22772860 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL94807 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29371885 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL8097 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL23633189 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL21544535 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL22468601 | 0.96 | FNTA (0.74) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL12021666 | 0.95 | FNTA (0.72) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3332 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106552-A1 | THERAPEUTIC CONVERSION OF CANCER CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-05-21 | — | — | WO | claimed |
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-4635574-A2 | COMBINATION THERAPY TO TREAT KRAS MUTANT CANCERS | Semmelweis Egyetem (HU) | 2025-10-22 | — | — | EP | claimed |
| US-12364766-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025101692-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR ANOMALIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-05-15 | — | — | WO | claimed |
| EP-3324856-B1 | SHEAR-THINNING COMPOSITIONS AS AN INTRAVASCULAR EMBOLIC AGENT | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-04-23 | — | — | EP | claimed |
| US-20220280807-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW BIO, LLC | 2022-09-08 | — | — | US | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220233713-A1 | SONODYNAMIC THERAPY | CALLAN JOHN (GB) | 2022-07-28 | — | — | US | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| WO-2022109601-A1 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | OBI PHARMA, INC. (TW) | 2022-05-27 | — | — | WO | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3946338-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMAS WITH FARNESYLTRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3942097-A1 | CHMP2A AS A REGULATOR OF NATURAL KILLER CELL-MEDIATED ACTIVITY | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | claimed |